Both the 2.5 μM and 10 μM doses of MT3 reduced the amount of relative myopia (right–left eyes), compared to the FD group (Figure 1; FD −5.40 ± 1.10 D, 2.5 μM −3.00 ± 0.50 D, 10 μM −1.35 ± 0.53 D), with both doses reaching significance (p < 0.001 for both). The gene discussed is MT3; the disease is myopia.